Seminars in Oncology
Volume 36, Issue 4 , Pages 290-301, August 2009

Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical IssuesDisclosures

  • Peter Reichardt

      Affiliations

    • Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    • These authors contributed equally to this work.
  • ,
  • Pancras C.W. Hogendoorn

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • These authors contributed equally to this work.
  • ,
  • Elena Tamborini

      Affiliations

    • Laboratory of Experimental Molecular Pathology, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Massimo Loda

      Affiliations

    • Dana-Farber Cancer Institute, Boston, MA
    • These authors contributed equally to this work.
  • ,
  • Alessandro Gronchi

      Affiliations

    • Department of Surgery, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Andrés Poveda

      Affiliations

    • Instituto Valenciano de Oncología, Valencia, Spain
    • These authors contributed equally to this work.
  • ,
  • Patrick Schöffski

      Affiliations

    • University Hospitals Leuven, Department of General Medical Oncology and Laboratory of Experimental Oncology Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Patrick Schöffski, MD, MPH, University Hospitals Leuven, Department of General Medical Oncology and Laboratory of Experimental Oncology, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, B-3000 Leuven, Belgium

Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate, or those arising from small bowel and colon/rectum is particularly high. The natural history, pathology, and molecular biology of GISTs are discussed in this review, as are features of increasing our analytical power of the genes altered in these tumors, surgical issues, and the translation of research findings into clinical practice. The biological features of GIST make it a model for the examination of kinase-targeted therapeutics in solid tumors.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

Disclosures P. Reichardt: Pfizer, Novartis (honoraria); research funding (Novartis)A. Gronchi: Novartis (honoraria)P. Schöffski: Pfizer (honoraria and research funding); Novartis (honoraria and research funding)Other authors: no significant relationships

PII: S0093-7754(09)00102-X

doi:10.1053/j.seminoncol.2009.06.002

Seminars in Oncology
Volume 36, Issue 4 , Pages 290-301, August 2009